Core Viewpoint - The Shanghai Stock Exchange has issued guidelines to support commercial rocket companies in meeting the fifth set of listing standards on the Sci-Tech Innovation Board, aiming to enhance the inclusivity and adaptability of the system for technology-driven enterprises [1][4]. Group 1: Guidelines Overview - The guidelines consist of fourteen articles that detail the requirements for commercial rocket companies under the fifth set of listing standards, emphasizing the importance of "hard technology" attributes [4]. - The main business scope is defined as "independent research, manufacturing, and provision of space launch services for commercial rockets," with a focus on the issuer's technological capabilities [4]. - Companies must demonstrate significant advantages or breakthroughs in key core technologies, including the ability to launch multiple satellites with a single rocket [4][5]. Group 2: Specific Requirements - Companies are required to achieve at least one successful launch of a medium to large reusable rocket with payload into orbit as a milestone before applying [5]. - The guidelines stipulate that commercial rockets must have a systematic approval and regulatory framework, including necessary qualifications and launch permits [5]. - Companies should hold a leading position in the industry, gaining recognition from relevant market entities and attracting investments from experienced professional institutions [5]. Group 3: Market and Commercialization - The guidelines require that the commercial rocket business or products have a clear target market and possess a first-mover advantage over competitors [5]. - A clear and feasible commercialization plan must be established for the transition from technology validation to large-scale operations, without significant adverse impacts on the business [5]. - The Shanghai Stock Exchange emphasizes the need for capital market support for the commercial rocket industry, which has high research and development costs and long cycles, and has not yet achieved large-scale commercialization [9].

人民财讯12月26日电，12月26日，上海证券交易所发布《上海证券交易所发行上市审核规则适用指引第 9号——商业火箭企业适用科创板第五套上市标准》，明确适用科创板第五套上市标准的商业火箭企业 主营业务为"商业火箭自主研发、制造及航天发射服务"，更加看重发行人的"硬科技"属性。要求企业需 在拥有关键核心技术基础上具备明显技术优势或重大突破，关注核心技术产品以及关键部件的自主研发 情况，以及运载能力及一箭多星能力等关键指标。对于承担国家任务、参与国家工程项目的商业火箭企 业予以优先支持。 ...

Group 1 - The core point of the news is that the commercial aerospace market in China is experiencing significant growth, with over 600 companies in the sector and several unicorns preparing for IPOs, including Blue Arrow Aerospace, which has completed its IPO counseling process [1][2][3] - The recent policy changes, particularly the expansion of the Sci-Tech Innovation Board's fifth listing standard, are encouraging unprofitable companies in cutting-edge fields like commercial aerospace to go public, leading to a surge in IPO preparations [1][4][3] - The commercial aerospace industry is characterized by high initial investment and long development cycles, but it has substantial future growth potential, with projections indicating that the market size for China's rocket industry could reach hundreds of billions by 2027 [4][5] Group 2 - More than ten commercial aerospace companies have initiated the IPO process, with several already undergoing counseling with local securities regulatory authorities [2][5] - Major brokerage firms are actively competing for participation in the IPO projects of commercial aerospace unicorns, indicating a strong interest in this sector [3][11] - The Chinese commercial aerospace market is expected to reach a scale of 1.2 trillion yuan by 2024, with a compound annual growth rate of approximately 18% projected until 2030 [7][8] Group 3 - The majority of the companies rushing to IPO were established between 2015 and 2018, coinciding with government policies that encouraged the development of private enterprises in the commercial aerospace sector [5][6] - The recent launch of multiple supportive policies by various provinces aims to promote the high-quality development of the commercial aerospace industry [7] - The competitive landscape is intensifying, with significant funding events recorded in 2024, totaling 202.39 billion yuan, marking a historical high in financing activities within the sector [9][10]

Core Viewpoint - The article highlights the revival of the IPO market for pharmaceutical companies on the STAR Market, particularly focusing on the successful turnaround of Beixin Life Technology Co., Ltd. and the ongoing interest in companies meeting the fifth set of listing standards [1][3]. Group 1: Company Developments - Beixin Life has achieved profitability after previously reporting losses, with a revenue of 128 million yuan in Q1, representing a year-on-year increase of 104.9%, and a net profit of 20.61 million yuan [3][4]. - The company’s IPO was accepted on March 30, 2023, and it successfully registered on December 18, 2023, marking it as the closest to listing among the eight pharmaceutical companies currently in the IPO queue [3][6]. - Other companies in the queue include Tianomab and Xinnowei, with Tianomab being the first to be accepted under the new standards, focusing on blood product alternatives [4][5]. Group 2: Market Trends - A total of eight pharmaceutical companies are currently in the IPO queue, all applying under the fifth set of standards, indicating a renewed interest in the sector [3][6]. - Seven out of the eight companies have already launched products, showcasing a shift from previous years where uncommercialized products were more common among IPO applicants [9][10]. - The regulatory environment has evolved to support unprofitable pharmaceutical companies, focusing on their technological capabilities, market potential, and financial sustainability [10][11]. Group 3: Financial Insights - Tianomab's core product, a monoclonal antibody, was approved in February 2023 but has seen lower-than-expected sales, achieving only 47.6% of its projected sales volume from March to September [9]. - Xinnowei is the only company in the queue without a product on the market, with its first drug expected to be approved by 2026 [9][10]. - Hengrun Da's financial health is concerning, with an increasing debt ratio projected to reach 84.76% by 2024, highlighting the risks associated with prolonged IPO delays [7][9].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has achieved profitability and is preparing for its IPO, marking a significant development in the medical device sector under the fifth set of listing standards on the STAR Market [1][2] Group 1: Company Developments - Beixin Life has registered its IPO as of December 18, 2023, and is focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [2] - The company reported a revenue of 128 million yuan in Q1 2023, a year-on-year increase of 104.9%, and achieved a net profit of 20.61 million yuan, indicating a turnaround from previous losses [2] - The IPO process for Beixin Life began on March 30, 2023, and it received approval on July 18, 2023, reflecting a shift in regulatory attitudes towards unprofitable medical enterprises [2][3] Group 2: Market Activity - As of December 25, 2023, there are eight pharmaceutical companies queued for IPO on the STAR Market, all applying under the fifth set of standards [2][4] - Five unprofitable pharmaceutical companies have received IPO acceptance this year, including Tianomab, which was the first to be accepted after the resumption of the fifth set of standards [3][4] - Among the queued companies, seven have already launched products, indicating a trend where unprofitable companies are not necessarily lacking in commercialization [7] Group 3: Financial Insights - Tianomab's core product, a monoclonal antibody, was approved in February 2023, but its sales performance has been below expectations, with only 47.6% of projected sales achieved from March to September 2023 [7] - The financial health of companies like Hengrun Da Sheng is concerning, with an increasing debt-to-asset ratio projected to reach 84.76% by 2024 [6] - The regulatory focus for unprofitable pharmaceutical companies includes assessing technological robustness, market potential, financial sustainability, and delisting risks [8]

| 卫星互联网 | | | 大飞机 +4.70% | | 卫星导航 +3.90% | +3.85% | | --- | --- | --- | --- | --- | --- | --- | | 十大军工集 人形机器人 | | | | 通用航空 +3.27% | +3.22% | +3.17% | | | 商业航天 +4.95% 低空经济 +3.76% 航母 +3.59% | | | | | | | | | 军工信息化 +3.38% 中航系 | | | | | | T 4.0 | | | 宇树机器人 | | 汽车配件精 | | | +2.65% | | +3.15% | | +3.03% | +2.78% | | | G | 商业航天指数(8841877) | | | | --- | --- | --- | --- | | | 19392.20 914.87 4.95% | | | | 资料 | 成分 资讯 相关基金 | | 月度收益 | | 名称 | | 现价 | 涨跌幅 == | | 超捷股份 | | 134.93 | 20.00% | | 301005.SZ | | | | | 广联航空 | | 31. ...

商业航天领域IPO再传来重磅进展。 近日，证监会网站显示，蓝箭航天IPO辅导状态已变更为"辅导工作完成"，距离正式递表仅一步之遥。 当前，商业航天市场热度持续高涨。目前国内商业航天企业数量已超600家，覆盖卫星制造、火箭发 射、地面设备、终端应用全产业链。 今年 6 月，科创板"1+6"改革规则落地，重启未盈利企业适用科创板第五套标准上市并扩大适用范围， 明确支持人工智能、商业航天、低空经济等更多前沿科技领域企业上市，商业航天企业开始扎堆筹备 IPO。 据21世纪经济报道记者不完全统计，目前已有十余家商业行业企业启动了IPO进程。除了蓝箭航天外， 星河动力、中科宇航、微纳星空、屹信航天、天兵科技、爱思达航天、星际荣耀均已在当地证监局进行 辅导，拟冲刺 A 股上市；另外国星宇航、福信富通则将目标瞄准了港股。 各大券商显然也不想错过这轮IPO新机遇，竞相参与到商业航空"独角兽"上市项目的争夺中。 "其实前两年，市场就已经出现了将科创板第五套上市标准扩围至商业航天领域的呼声，有很多同行从 那个时候就开始注意这个领域的项目。科创板新政的出台，就是一个'起跑信号'，前期有项目储备的走 得很快。"华南一名资深的保代受访表 ...

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (Tainuo Maibo) has become a market focus as the first company to apply for listing under the fifth set of standards for the Science and Technology Innovation Board (STAR Market) after its restart. The company disclosed its first round of inquiry responses, revealing that the actual sales of its core product, Staidotat Monoclonal Antibody, fell short of expectations, achieving only 47.6% of the projected sales volume [1][4][5]. Sales Performance - As of September 30, the actual sales of Staidotat Monoclonal Antibody were 4.61 million bottles, compared to an expected 9.69 million bottles, resulting in a completion ratio of 47.6% [5][6]. - The self-operated team had an expected sales volume of 5.68 million bottles but achieved only 4.35 million bottles (completion ratio of 76.67%), while the external promotion service team expected 4.01 million bottles but only sold 0.26 million bottles (completion ratio of 6.42%) [5][6]. Financial Overview - Tainuo Maibo's sales expenses are significant, with projected sales expenses of 3.89 million, 12.42 million, and 35.11 million for the years 2022 to 2024, respectively. In the first quarter of this year, sales expenses reached 24 million [7][8]. - The company reported a net loss of approximately 4.29 billion, 4.46 billion, and 5.15 billion for the years 2022 to 2024, with a net loss of about 1.77 billion in the first quarter of this year [8]. Debt and Financial Health - The asset-liability ratio of Tainuo Maibo has significantly increased, with ratios of 16.54%, 28.19%, 58.96%, and 56.5% for the years 2022 to 2025 Q1. This ratio is higher than the average of comparable companies [10][11]. - The increase in the asset-liability ratio is attributed to increased spending on drug research and commercialization team building, alongside a decrease in cash reserves [12]. IPO and Fundraising - Tainuo Maibo aims to raise 1.5 billion for new drug research projects, expansion of antibody production bases, and to supplement working capital, with allocations of 830 million, 330 million, and 340 million, respectively [9].

Core Points - Shenzhen Core Medical Technology Co., Ltd. has become the first innovative medical device company to submit an IPO application under the reactivated fifth set of listing standards for the Sci-Tech Innovation Board [1][5] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [3][4] - Core Medical has developed 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized and two interventional products in the registration approval stage [3][4] Financial Performance - Core Medical has not yet achieved profitability, with projected revenues of approximately 0, 16.55 million, 93.69 million, and 70.48 million CNY for the years 2022 to 2025, and net losses of approximately -178 million, -170 million, -132 million, and -72.75 million CNY for the same periods [4] - As of June 30, the company reported cumulative undistributed profits of -367 million CNY, indicating ongoing financial challenges [4] Market Position and Challenges - The artificial heart industry in China is still in its early development stages, with commercialization affected by factors such as clinical penetration, discipline development, surgical promotion, and patient payment capabilities [4] - Core Medical aims to become the first company to obtain approval for interventional artificial heart products in China, facing challenges in product promotion, market education, and brand building [4][5] IPO Details - The company plans to raise up to 1.217 billion CNY through its IPO, with funds allocated for research and development of circulatory support products, establishment of an artificial heart industrialization base, marketing network and digital construction, and working capital [5] - Core Medical meets the listing standards set forth in the Sci-Tech Innovation Board's regulations, which emphasize technological advancement and research capabilities over short-term financial metrics [5]

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the newly reinstated fifth set of listing standards for the Sci-Tech Innovation Board [1] Group 1 - Core Medical has received investments from multiple seasoned professional institutional investors [1] - It is the second company to be recognized as having seasoned professional institutional investors after Zhuhai Tenomab Pharmaceutical Co., Ltd. [1]